TOKYO - A single course of treatment with an Alzheimer's drug developed by Japanese company Eisai Co. and U.S. firm Biogen Inc. will cost around 2.98 million yen ($20,500) per year in Japan and will be largely covered by public health insurance, a health ministry body said Wednesday.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
